MET and bile duct cancer: However, secondary mutations and acquired resistance to FGFR2 and IDH1 targeted therapies, along with the high toxicities observed in a phase II trial with cabozantinib, which targets VEGFR2, MET and AXL, indicate that it is crucial to identify new, specific targeted therapies that possess less normal tissue toxicity to treat bile duct cancer [8,9,10].